GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)

While their glycemic, weight-lowering, and cardiovascular benefits are well established through randomized trials and meta-analyses, concerns remain regarding their safety and tolerability across diverse populations and clinical settings
However, 2025 has marked a pivotal turning point, characterized by a significant weight loss drug price drop 2025
Fat Loss: L-carnitine assists in the transport of fatty acids into cells for energy production, stimulating fat oxidation